Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: Possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors

Pharmacology

Volumn 88, Issue 1-2, 2011, Pages 1-9

  Yang, Si Hyung ^a   Choi, Jun Shik ^b   Choi, Dong Hyun ^b  

^a Dankook University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

CYP3A subfamily; HMG CoA reductase inhibitors; Losartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ATORVASTATIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; LOSARTAN; PRAVASTATIN; RHODAMINE 123; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACYL COENZYME A; ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; LOSARTAN; LOVASTATIN; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; SIMVASTATIN; TETRAZOLES; TIME FACTORS;

EID: 79959570024     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000328773     Document Type: Article

References (26)

1. Koh KK, Quon MJ, Waclawiw MA: Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008; 196: 1-8.
2. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP: Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007; 9: 175-183. (Pubitemid 46894811)
3. Prueksaritanont T, Gorham LM, Ma B: In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-1199. (Pubitemid 27446590)
4. Transon C, Leemann T, Dayer P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-215.
5. Lea AP, McTavish D: Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53; 828-847. (Pubitemid 27195013)
6. Holtzman CW, Wiggins BS, Spinler SA: Role of P-glycoprotein in statin drug interaction. Pharmacotherapy 2006; 26: 1601-1607. (Pubitemid 44704473)
7. McIntyre M, Caffe SE, Michalak RA, Reid JL: Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181-194. (Pubitemid 27337347)
8. Yasar U, Tybring G, Hidestrand M, et al: Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29: 1051-1056. (Pubitemid 32605922)
9. Soldner A, Hildegard SL, Mutschler E: HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP-3174 in biological material of humans and rats. J Pharm Biomed Anal 1998; 16: 863-873. (Pubitemid 28097414)
10. Soldner A, Christians U, Susanto M, et al: Grapefruit juice activates P-glycoproteinmediated drug transport. Pharm Res 1999; 16: 478-485. (Pubitemid 29191290)
11. Mousa O, Brater DC, Sunblad KJ, Hall SD: The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-274. (Pubitemid 30176385)
12. Zarghi A, Foroutan SM, Shafaati A, Khoddam A: A rapid HPLC method for the determination of losartan in human plasma using a monolithic column. Arzneimittelforschung 2005; 55: 569-572. (Pubitemid 41546101)
13. Crespi CL, Miller VP, Penman BW: Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997; 248: 188-190. (Pubitemid 27218241)
14. Han CY, Cho KB, Choi HS, et al: Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008; 29: 1837-1844.
15. Gibaldi M, Perrier D: Pharmacokinetics, ed 2. New York, Marcel-Dekker, 1982.
16. Chiou WL: Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
17. Cummins CL, Jacobsen W, Benet LZ: Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-1045. (Pubitemid 34165010)
18. Mason RP: A rationale for combined therapy with a calcium channel blocker and a statin: Evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 489-501. (Pubitemid 43008522)
19. Shibasaki M, Fujimori A, Takanashi M, et al: Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist. Eur J Pharmacol 1997; 335: 167-173. (Pubitemid 27450482)
20. Kobayashi M, Takagi M, Fukumoto K, et al: The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 2008; 23: 115-119.
21. Yun CH, Lee HS, Lee H, et al: Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995; 23: 285-289.
22. Yoshitani T, Yagi H, Inotsume N, Yasuhara M: Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull 2002; 25: 1077-1083. (Pubitemid 39663236)
23. Azie NE, Brater DC, Becker PA, et al: The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-377. (Pubitemid 28473762)
24. Choi DH, Li C, Choi JS: Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet 2009; 34: 163-168.
25. Neuvonen PJ, Kantola T, Kivistö KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341. (Pubitemid 28182231)
26. Fukazawa I, Uchida N, Uchida E, Yasuhara H: Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2004; 57: 448-455. (Pubitemid 38519650)